Copy to clipboard 
OrthoPediatrics reported 3Q19 revenue of USD $20.7 million, +31.1% vs. 3Q18.
- The company raised 2019 full-year guidance to the range of $70.8 (+23%) to $71.9 million (+25%)
- Recent product introductions like the small stature scoliosis system and BandLoc DUO made 3Q19 the highest revenue quarter in the company’s history
- Three surgeons who were out of practice returned to a limited volume at new institutions and helped drive incremental revenues in the quarter
- The OrthoPediatrics salesforce grew by 21% to 158 consultants
- Through nine months in 2019, the company has deployed $13.7 million in instrument sets, an increase of 29% vs. the same period in 2018
- Started shipping two new cannulated screw systems in September 2019 and expects to launch the PediFoot pediatric foot and ankle solution later in November 2019
- Leadership is pleased with the first full quarter of owning Vilex, and expects to divest all adult assets by year-end; will continue to explore further acquisitions to complement their pediatric portfolio
- OrthoPediatrics sees a comparatively softer 4Q, in line with seasonal expectations for pediatrics
- ORTHOWORLD projects OrthoPediatrics full year 2019 revenue of $71.8 million, +24.8% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $6.5 | $5.0 | $1.4 | 28.7% |
| Trauma | $13.8 | $10.6 | $3.3 | 31% |
| Sports Medicine | $0.4 | $0.2 | $0.2 | 89.6% |
| Total | $20.7 | $15.8 | $4.9 | 31.1% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $16.6 | $12.6 | $4.0 | 31.6% |
| Trauma | $35.7 | $29.5 | $6.2 | 21% |
| Sports Medicine | $1.3 | $0.8 | $0.4 | 51.3% |
| Total | $53.6 | $43.0 | $10.6 | 24.7% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $16.8 | $12.4 | $4.4 | 35.1% |
| Ex-US | $4.0 | $3.4 | $0.6 | 16.5% |
| Total | $20.7 | $15.8 | $4.9 | 31.1% |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $20.7 | |
| Cost of Sales | ($4.8) | 23.4% |
| General and Admin | ($7.3) | 35% |
| Selling and Marketing | ($8.8) | 42.3% |
| R & D | ($1.4) | 6.7% |
| Other | ($1.1) | 5.4% |
| Net Earnings | ($2.7) | (12.8%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
OrthoPediatrics reported 3Q19 revenue of USD $20.7 million, +31.1% vs. 3Q18.
The company raised 2019 full-year guidance to the range of $70.8 (+23%) to $71.9 million (+25%)
Recent product introductions like the small stature scoliosis system and BandLoc DUO made 3Q19 the highest revenue quarter in the company’s history
Three...
OrthoPediatrics reported 3Q19 revenue of USD $20.7 million, +31.1% vs. 3Q18.
- The company raised 2019 full-year guidance to the range of $70.8 (+23%) to $71.9 million (+25%)
- Recent product introductions like the small stature scoliosis system and BandLoc DUO made 3Q19 the highest revenue quarter in the company’s history
- Three surgeons who were out of practice returned to a limited volume at new institutions and helped drive incremental revenues in the quarter
- The OrthoPediatrics salesforce grew by 21% to 158 consultants
- Through nine months in 2019, the company has deployed $13.7 million in instrument sets, an increase of 29% vs. the same period in 2018
- Started shipping two new cannulated screw systems in September 2019 and expects to launch the PediFoot pediatric foot and ankle solution later in November 2019
- Leadership is pleased with the first full quarter of owning Vilex, and expects to divest all adult assets by year-end; will continue to explore further acquisitions to complement their pediatric portfolio
- OrthoPediatrics sees a comparatively softer 4Q, in line with seasonal expectations for pediatrics
- ORTHOWORLD projects OrthoPediatrics full year 2019 revenue of $71.8 million, +24.8% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $6.5 | $5.0 | $1.4 | 28.7% |
| Trauma | $13.8 | $10.6 | $3.3 | 31% |
| Sports Medicine | $0.4 | $0.2 | $0.2 | 89.6% |
| Total | $20.7 | $15.8 | $4.9 | 31.1% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $16.6 | $12.6 | $4.0 | 31.6% |
| Trauma | $35.7 | $29.5 | $6.2 | 21% |
| Sports Medicine | $1.3 | $0.8 | $0.4 | 51.3% |
| Total | $53.6 | $43.0 | $10.6 | 24.7% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $16.8 | $12.4 | $4.4 | 35.1% |
| Ex-US | $4.0 | $3.4 | $0.6 | 16.5% |
| Total | $20.7 | $15.8 | $4.9 | 31.1% |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $20.7 | |
| Cost of Sales | ($4.8) | 23.4% |
| General and Admin | ($7.3) | 35% |
| Selling and Marketing | ($8.8) | 42.3% |
| R & D | ($1.4) | 6.7% |
| Other | ($1.1) | 5.4% |
| Net Earnings | ($2.7) | (12.8%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
